Form 4: Edwards Lifesciences CFO Scott Ullem Reports Stock Transaction

Sentiment:

SEC Form 4 Filing


CVP, Chief Financial Officer of Edwards Lifesciences, Scott B. Ullem, reports a transaction involving company stock on February 16, 2025.

Summary

  • On February 16, 2025, Scott B. Ullem, the CVP and Chief Financial Officer of Edwards Lifesciences Corp, engaged in a transaction involving the company's common stock.
  • A total of 174 shares were disposed of at a price of $76.19.
  • Following the transaction, Ullem directly owns 30,387 shares of common stock and indirectly owns 266,318 shares through a trust.

Sentiment

Score: 5

Explanation: This is a neutral report of a stock transaction. It doesn't inherently indicate positive or negative sentiment about the company's performance.

Industry Context

This is a routine disclosure of a transaction by a company insider, as required by the SEC. It doesn't necessarily indicate a change in the company's prospects but provides transparency into the actions of key personnel.

Key Dates

DateDescription
02/16/2025Date of stock transaction
02/18/2025Date of signature by Attorney-in-Fact

Keywords

Form 4, Edwards Lifesciences, Stock Transaction, Beneficial Ownership, Scott B. Ullem, CFO, EW

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.